Get the Stockscreener App
18.32
0.47%
0.0855
Mediwound Ltd stock is traded at $18.32, with a volume of 5,034.
It is up +0.47% in the last 24 hours and down -2.37% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$18.23
Open:
$18.28
24h Volume:
5,034
Relative Volume:
0.08
Market Cap:
$198.11M
Revenue:
$19.85M
Net Income/Loss:
$-12.75M
P/E Ratio:
-13.27
EPS:
-1.38
Net Cash Flow:
$-21.94M
1W Performance:
+8.18%
1M Performance:
-2.37%
6M Performance:
+3.54%
1Y Performance:
+21.29%
1-Day Range:
$18.18
$18.38
1-Week Range:
$16.00
$18.38
52-Week Range:
$12.78
$24.00
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
18.38 | 198.11M | 19.85M | -12.75M | -21.94M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
508.66 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
676.17 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
598.61 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
257.87 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | Craig Hallum | Buy |
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
MediWound (MDWD) Projected to Post Earnings on Wednesday - Defense World
MediWound Ltd. (NASDAQ:MDWD) Shares Acquired by Rhumbline Advisers - Defense World
MediWound Ltd. to Host Earnings Call - ACCESS Newswire
MediWound at TD Cowen Conference: Strategic Insights on Growth - Investing.com India
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
When Will MediWound Reveal Its 2024 Financial Performance? Key Date Announced - StockTitan
MediWound (NASDAQ:MDWD) Research Coverage Started at Craig Hallum - Defense World
MediWound (NASDAQ:MDWD) Now Covered by Analysts at Craig Hallum - MarketBeat
Craig-Hallum sets $39 target on MediWound stock with buy rating - Investing.com Canada
(MDWD) Investment Report - Stock Traders Daily
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Craig-Hallum sets $39 target on MediWound stock with buy rating By Investing.com - Investing.com South Africa
Laurentian Bank of Canada declares dividend on its common shares - The Globe and Mail
Burns Pipeline 2024: Therapies, MOA Insights, and Key Clinical - openPR
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care - GlobeNewswire
Can NexoBrid Transform Pediatric Burn Care? Phase III Results Show Superiority - StockTitan
MediWound to Present at the 45th Annual TD Cowen Health Care Conference - GlobeNewswire
Can MediWound's Tissue Repair Innovation Reshape the Healthcare Market? CEO Reveals Strategy - StockTitan
(MDWD) Trading Signals - Stock Traders Daily
MediWound stock climbs 4% on Phase 3 study initiation - MSN
MediWound begins pivotal Phase III trial for wound therapy By Investing.com - Investing.com Nigeria
MediWound begins pivotal Phase III trial for wound therapy - MSN
MediWound Launches Phase III Trial Evaluating EscharEx for Treating Venous Leg Ulcers - Marketscreener.com
Mediwound’s EscharEx Shows Promising Results in Phase 3 Trial - TipRanks
MediWound Launches Phase III Trial for EscharEx Targeting Venous Leg Ulcers - TipRanks
MediWound to launch Phase III trial for venous leg ulcers -February 12, 2025 at 07:00 am EST - Marketscreener.com
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers - GlobeNewswire
EscharEx Clinical Trial: MediWound's Groundbreaking Solution for $375M Venous Ulcer Market - StockTitan
Is MediWound (NASDAQ:MDWD) In A Good Position To Invest In Growth? - Simply Wall St
JPMorgan Chase & Co. Has $61,000 Stock Position in MediWound Ltd. (NASDAQ:MDWD) - MarketBeat
How the (MDWD) price action is used to our Advantage - Stock Traders Daily
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Exclusive: MediWound CEO to Reveal Latest Tissue Repair Innovations at Major Healthcare Conference - StockTitan
JPMorgan Chase & Co. Sells 75,360 Shares of MediWound Ltd. (NASDAQ:MDWD) - Defense World
MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week - Yahoo Finance
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains? - Yahoo Finance
Barclays PLC Increases Stock Holdings in MediWound Ltd. (NASDAQ:MDWD) - Defense World
BioHarvest Sciences Strengthens Board with Healthcare Industry Veteran Sharon Malka - StockTitan
Burns Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corp - The Globe and Mail
Trading (MDWD) With Integrated Risk Controls - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for MediWound (NASDAQ:MDWD) - Defense World
MediWound (NASDAQ:MDWD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions - Yahoo Finance
MediWound Ltd.'s (NASDAQ:MDWD) P/S Still Appears To Be Reasonable - Simply Wall St
Geode Capital Management LLC Sells 2,365 Shares of MediWound Ltd. (NASDAQ:MDWD) - Defense World
Barclays PLC Raises Stake in MediWound Ltd. (NASDAQ:MDWD) - Defense World
When (MDWD) Moves Investors should Listen - Stock Traders Daily
State Street Corp Raises Holdings in MediWound Ltd. (NASDAQ:MDWD) - Defense World
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):